She joined Novartis more than 20 years ago and has led several of the company’s oncology businesses over the last six years, including region head of Novartis Oncology Europe.

Loomis Sayles, an investment management company, released its “Global Growth Fund” first quarter 2025 investor letter. A copy ...

With the goal to become a top 3 pharma company in China, Novartis has been busy tapping into the expertise of local ...

With much still to discover in the massive world of radiopharmaceuticals, Novartis will take a deep dive into the unknown with Mariana Oncology in a $1 billion upfront acquisition. With Novartis ...

Swiss pharma giant Novartis will spotlight key data across its oncology portfolio, including Kisqali (ribociclib), Scemblix (asciminib) and Pluvicto (lutetium Lu 177 vipivotide tetraxetan), which was ...

So, Kisqali (ribociclib) is one of the key medicines in Novartis' oncology portfolio that has received approval from the FDA and other agencies. It is for the treatment of people with breast ...

Novartis is adding on to its capabilities in radiopharmaceuticals through a deal to acquire Mariana Oncology, a startup with a drug pipeline and technologies that diversify the pharmaceutical ...

Novartis has restructured to focus solely on innovative branded drugs, showing double-digit growth in revenue and profit in 2024. The company is strong in oncology, cardiology, immunology ...

Novartis' strategy to focus largely in areas of unmet medical need should strengthen the firm's pricing power. The firm's key areas of innovation focus on oncology, immunology, neurology ...